Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma

European Journal of Haematology

Volumn 78, Issue 4, 2007, Pages 330-337

  Bruno, Benedetto ^a,e   Sorasio, Roberto ^a   Patriarca, Francesca ^b   Montefusco, Vittorio ^c   Guidi, Stefano ^d   Busca, Alessandro ^e   Scimé, Rosanna ^f   Console, Giuseppe ^g   Milone, Giuseppe ^h   Marotta, Giuseppe ⁱ   Dominietto, Alida ^j   Giaccone, Luisa ^a   Rotta, Marcello ^a   Falda, Michele ^e   Bacigalupo, Andrea ^j   Bosi, Alberto ^d   Corradini, Paolo ^c   Fanin, Renato ^b   Pollichieni, Simona ^k   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h Ferrarotto Hospital   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

^k Italian Bone Marrow Donor Registry ^*  (Italy)

more..

Author keywords

Allogeneic transplantation; Engraftment; Graft vs. host disease; Multiple myeloma; Non myeloablative transplantation; Unrelated donors

Indexed keywords

CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CLINICAL ARTICLE; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MALE; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REMISSION; SALVAGE THERAPY; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33847623594     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00816.x     Document Type: Article

References (31)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
3. Moreau P, Misbahi R, Milpied N, Morineau N, Mahe B, Vigier M, Rapp MJ, Bataille R, Harousseau JL. Longterm results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 2002;16:1838- 43.
4. Fassas A, Tricot G. Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol 2001;38:231-42. Review.
5. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36.
6. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-22.
7. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-16.
8. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
9. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021-30.
10. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447- 54.
11. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003;16:647-57. Review.
12. Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd edn. Boston, MA: Blackwell Science, 1999:515-36.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
15. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L, Liebisch P, Bamberg M, Faul C, Kanz L. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003;121:411-8.
16. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105:4532-9.
17. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006;12:454-65.
18. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295-303.
19. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919-24.
20. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003;9:257-65.
21. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474- 80.
22. Laterveer L, Verdonck LF, Peeters T, Borst E, Bloem AC, Lokhorst HM. Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma. Blood 2003;101:1201-2.
23. Kroger N, Perez-Simon JA, Myint H, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/ fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004;10:698-708.
24. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003;31:73-80.
25. Siegel S, Wagner A, Friedrichs B, et al. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 2006;76:6935-44.
26. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Boccadoro M. New drugs for treatment of multiple myeloma. Lancet Oncol 2004;5:430-42. Review.
27. Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104:3361-3.
28. Mattei D, Mordini N, Vigna Taglianti R, Bruno B, Rapezzi D, Gallamini A. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse. Haematologica 2005;90:861-2.
29. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005;90:278-79.
30. van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006;107:3415-6.
31. Bruno B, Patriarca F, Sorasio R, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006;91:837-9.